Product Reports Resources Pricing Login Book a demo

BioNTech

Biotech & Life Sciences · Mainz, Germany · Founded 2008 · IPO 2019

Develops personalized immunotherapies with a focus on cancer medicine

Valuation $6.39B
Revenue $2.38B

Talent graph

BioNTech's talent

Book a demo to see the people
Employees mapped 5,205 incl. 76 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 36 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

17 investors on BioNTech's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage
ATHOS Venture
MIG Capital
Santo Holding
Series A 6 investors entered at this stage
Invus
Redmile Group
Janus Henderson Investors
Eli Lilly
Janus Henderson
Fidelity Investments
Series B+ 8 investors entered at this stage
Platinum Asset Management
Johannes Gutenberg University Mainz
Jebsen Capital
Mirae Asset Venture Investment
Temasek
Sanofi
Genentech
Bayer

Global footprint

Where BioNTech has talent and traffic

Workforce by country
39 countries with
team presence
🇩🇪 Germany75.4%
🇺🇸 United States16.5%
🇬🇧 United Kingdom2.4%
🇸🇬 Singapore1.4%
🏳️ Rwanda0.7%
Top 5 of 39 shown
Web traffic by country
110K monthly visits
across markets
🇩🇪 Germany19.2%
🇺🇸 United States13.5%
🇦🇺 Australia12.4%
🇬🇧 United Kingdom8.4%
🇨🇦 Canada4.4%
Top 5 markets shown

Patent intelligence

$788M patent portfolio · 583 active families

Estimated portfolio value
$788M
12.3% of market cap · 4.2× larger than top peer Moderna Therapeutics ($189M)
583 active patent families
Where BioNTech innovates BioinformaticsCancer researchCarcinosisDiseaseMolecular biology

Where BioNTech concentrates vs peers

Each axis is a top-10 topic across BioNTech and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

BioNTech's 13 investments and acquisitions.

Every disclosed deal where BioNTech appeared as a backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

13 deals across BioNTech's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where BioNTech deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        BioNTech's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        13 of 13 deals

        Market sentiment

        What the market is saying about BioNTech

        An AI-synthesized read of the highest-engagement posts about BioNTech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioNTech on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.